{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T20:02:36Z","timestamp":1776110556464,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["GZB20250222"],"award-info":[{"award-number":["GZB20250222"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22376016"],"award-info":[{"award-number":["22376016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22022601"],"award-info":[{"award-number":["22022601"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bioorg.2026.109771","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:22:16Z","timestamp":1773825736000},"page":"109771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rational design and preclinical evaluation of 68Ga-labeled PEG-modified dimeric FAP radiotracers"],"prefix":"10.1016","volume":"175","author":[{"given":"Zehua","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongrui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengchao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bioorg.2026.109771_bb0005","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: targeting cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109771_bb0010","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.mibio.2004.06.004","article-title":"MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides","volume":"6","author":"Chen","year":"2004","journal-title":"Mol. Imaging Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109771_bb0015","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.7150\/thno.69475","article-title":"Fibroblast activation protein-based theranostics in cancer research: a state-of-the-art review","volume":"12","author":"Zhao","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109771_bb0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1042\/BST20160387","article-title":"Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis","volume":"45","author":"Erdogan","year":"2017","journal-title":"Biochem. Soc. Trans."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109771_bb0025","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.bioorg.2026.109771_bb0030","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1021\/acs.molpharmaceut.5c00979","article-title":"Synthesis, radiolabeling, and evaluation of a dimeric fibroblast activation protein inhibitor with a triazine linker","volume":"22","author":"Zhang","year":"2025","journal-title":"Mol. Pharm."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109771_bb0035","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A tumor-imaging method targeting cancer-associated fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.109771_bb0040","doi-asserted-by":"crossref","first-page":"1593380","DOI":"10.3389\/fphar.2025.1593380","article-title":"Based on small molecules: development and application of fibroblast activation protein inhibitors radiopharmaceutical in tumor precision therapy","volume":"16","author":"Luo","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109771_bb0045","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation protein in health and malignancy","volume":"39","author":"Fitzgerald","year":"2020","journal-title":"Cancer. Metast. Rev."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109771_bb0050","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/ml300410d","article-title":"Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold","volume":"4","author":"Jansen","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109771_bb0055","doi-asserted-by":"crossref","first-page":"9973","DOI":"10.1021\/acs.jmedchem.4c02961","article-title":"Design, synthesis, and evaluation of a novel positron emission tomography tracer targeting fibroblast activation protein: from bench to bedside","volume":"68","author":"Tang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109771_bb0060","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1021\/jm500031w","article-title":"Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP)","volume":"57","author":"Jansen","year":"2014","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109771_bb0065","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of fibroblast activation protein\u2013targeted radiotracers with improved tumor retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109771_bb0070","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109771_bb0075","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","article-title":"Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer","volume":"47","author":"Chen","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109771_bb0080","doi-asserted-by":"crossref","first-page":"12745","DOI":"10.1021\/acs.jmedchem.5c00637","article-title":"Rational design and preliminary evaluation of a radiopharmaceutical targeting fibroblast activation proteins [68Ga]Ga\/[177Lu]Lu-FAPI-JNU for tumor imaging and therapy","volume":"68","author":"Luo","year":"2025","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109771_bb0085","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1021\/acs.molpharmaceut.5c00464","article-title":"Structural optimization of fibroblast activation protein inhibitors through zwitterionic and peg modification strategy: impact on pharmacokinetics and tumor imaging","volume":"22","author":"Yuan","year":"2025","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109771_bb0090","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1021\/acs.bioconjchem.5c00366","article-title":"Synthesis and preclinical evaluation of druglike 18F-labeled fibroblast activation protein (FAP) inhibitors with enhanced tumor retention","volume":"36","author":"Adhikari","year":"2025","journal-title":"Bioconjug. Chem."},{"issue":"8015","key":"10.1016\/j.bioorg.2026.109771_bb0095","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","article-title":"Covalent targeted radioligands potentiate radionuclide therapy","volume":"630","author":"Cui","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109771_bb0100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s41181-020-00102-z","article-title":"Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators","volume":"5","author":"Moon","year":"2020","journal-title":"EJNMMI. Radiopharm. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2026.109771_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ph14121212","article-title":"First-in-human results on the biodistribution, pharmacokinetics, and dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2","volume":"14","author":"Ballal","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"10","key":"10.1016\/j.bioorg.2026.109771_bb0110","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1021\/acs.molpharmaceut.2c00424","article-title":"Development of fibroblast activation protein inhibitor-based dimeric radiotracers with improved tumor retention and antitumor efficacy","volume":"19","author":"Zhao","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioorg.2026.109771_bb0115","doi-asserted-by":"crossref","unstructured":"Bilinska, A.; Kumar, N.; Gnesin, S.; L\u00e4ppchen, T.; Men\u00e9ndez, E.; Martin, M.; R\u00f6sch, F.; Rominger, A.; Gourni, E., Preclinical evaluation of DOTAGA.Glu.(FAPI)2 and DO3A.Glu.(FAPI)2 as theranostics with human dosimetry extrapolation to lutetium-177 and terbium-161 analogs. Eur. J. Nucl. Med. Mol. Imaging. 2025, 53 (3), 1887-1901.","DOI":"10.1007\/s00259-025-07565-9"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109771_bb0120","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3390\/cancers15061889","article-title":"Novel generation of FAP inhibitor-based homodimers for improved application in radiotheranostics","volume":"15","author":"Martin","year":"2023","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109771_bb0125","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/10717540600814402","article-title":"Pharmacokinetic consequences of pegylation","volume":"13","author":"Hamidi","year":"2008","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109771_bb0130","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1186\/1556-276X-6-563","article-title":"Both FA- and mPEG-conjugated chitosan nanoparticles for targeted cellular uptake and enhanced tumor tissue distribution","volume":"6","author":"Hou","year":"2011","journal-title":"Nanoscale Res. Lett."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109771_bb0135","doi-asserted-by":"crossref","first-page":"862","DOI":"10.2967\/jnumed.121.263016","article-title":"Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of 68Ga-labeled FAPI dimer","volume":"63","author":"Zhao","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109771_bb0140","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2967\/jnumed.123.265599","article-title":"Development of FAPI tetramers to improve tumor uptake and efficacy of FAPI radioligand therapy","volume":"64","author":"Pang","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"13","key":"10.1016\/j.bioorg.2026.109771_bb0145","doi-asserted-by":"crossref","first-page":"8614","DOI":"10.1021\/acs.jmedchem.3c00259","article-title":"High affinity and FAP-targeted radiotracers: a potential design strategy to improve the pharmacokinetics and tumor uptake for FAP inhibitors","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109771_bb0150","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.apsb.2021.09.032","article-title":"Preclinical evaluation and pilot clinical study of [18F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts","volume":"12","author":"Hu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"13","key":"10.1016\/j.bioorg.2026.109771_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29133093","article-title":"Tailoring fibroblast-activation protein targeting for theranostics: a comparative preclinical evaluation of the 68Ga- and 177Lu-labeled monomeric and dimeric fibroblast-activation protein inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2","volume":"29","author":"Lappchen","year":"2024","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109771_bb0160","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1021\/acs.molpharmaceut.2c01051","article-title":"Inhibition of poly(adp-ribose) polymerase sensitizes [177Lu]Lu-DOTAGA.(SA.FAPi)2-mediated radiotherapy in triple-negative breast cancer","volume":"20","author":"Bao","year":"2023","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109771_bb0165","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1007\/s00259-024-06965-7","article-title":"Design, preclinical evaluation, and first-in-human PET study of [68Ga]Ga-PSFA-01: a PSMA\/FAP heterobivalent tracer","volume":"52","author":"Wang","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109771_bb0170","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1021\/acs.jmedchem.5c01166","article-title":"Biphenyl-trimeric PSMA theranostic platform enables PET imaging and optical detection of prostate cancer","volume":"68","author":"Chen","year":"2025","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109771_bb0175","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1021\/acs.jmedchem.4c02989","article-title":"Synthesis, preclinical evaluation, and first-in-human assessment of ICG-PSMA-D5: a PSMA-targeted probe for fluorescence-guided surgery of prostate cancer","volume":"68","author":"Chen","year":"2025","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600307X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600307X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T18:34:22Z","timestamp":1776105262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682600307X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":35,"alternative-id":["S004520682600307X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109771","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational design and preclinical evaluation of 68Ga-labeled PEG-modified dimeric FAP radiotracers","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109771","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109771"}}